Next-generation cancer vaccine approaches: Integrating lessons learned from current successes with promising biotechnologic advances

Research output: Contribution to journalArticle


With the recent approval of sipuleucel-T for metastatic castration-resistant prostate cancer and ipilimumab for metastatic melanoma, there is increasing excitement in the field of cancer immunotherapy. A large number of clinical trials are currently testing various vaccine vectors in a diverse array of cancer types. Which of these strategies will ultimately prove successful has yet to be determined. However, a better understanding of the complex interplay of tumor-specific T cells and the challenges faced at the tumor microenvironment, advances in biotechnology, and lessons learned from prior successes and failures will likely lead to approvals of other therapeutic cancer vaccines.

Original languageEnglish (US)
Pages (from-to)766-772
Number of pages7
JournalJNCCN Journal of the National Comprehensive Cancer Network
Issue number7
Publication statusPublished - Jul 1 2013


ASJC Scopus subject areas

  • Oncology

Cite this